Light AI Reports Q4 2025 Financial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 27 2026
0mins
Source: Yahoo Finance
- Operating Expense Reduction: In Q4 2025, Light AI reported operating expenses of CAD 2.3 million, a significant decrease from CAD 5.6 million in Q3 2025, primarily due to reduced marketing and product development costs, thereby enhancing the company's financial health.
- Annual Financial Growth: For the full year 2025, total operating expenses reached CAD 16.1 million, up from CAD 8.1 million in 2024, reflecting a substantial increase in marketing and investor relations expenditures following the company's public listing, indicating a strong commitment to market expansion.
- Cash Flow Status: As of December 31, 2025, Light AI had a cash balance of CAD 6.5 million, down from CAD 15.2 million in 2024, highlighting a need for improved capital efficiency in operations and marketing to support future commercialization efforts.
- Technological Progress and Market Opportunities: Light AI's QuickScan™ Strep A application is now commercially ready, with the CEO stating that the company is executing a dual-track strategy of advancing clinical trials and regulatory approvals to capture early leadership in a large, underserved global market, which is expected to drive future revenue growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CBOE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CBOE
Wall Street analysts forecast CBOE stock price to rise
8 Analyst Rating
2 Buy
5 Hold
1 Sell
Hold
Current: 255.980
Low
240.00
Averages
290.86
High
317.00
Current: 255.980
Low
240.00
Averages
290.86
High
317.00
About CBOE
Cboe Global Markets, Inc. is a derivatives and securities exchange network delivering trading, clearing, and investment solutions. The Company provides trading solutions and products in equities, derivatives, and foreign exchange (FX). Its segments include Options, North American Equities, Europe and Asia Pacific, Futures, and Global FX. The Options segment includes options on market indices, as well as on the stocks of individual corporations and on exchange-traded products (ETPs) such as exchange-traded funds (ETFs) and exchange-traded notes (ETNs), which are multi-listed options and listed on a non-exclusive basis. The North American Equities segment includes United States equities and ETP transaction services that occur on fully electronic exchanges. The Europe and Asia Pacific segment includes derivatives transaction services, ETPs, including exchange-traded funds, exchange-traded notes, exchange-traded commodities, and international depository receipts.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Binary Options Return: Cboe Global Markets has reintroduced binary options, allowing customers to choose whether the S&P 500 will hit a specific threshold in the near term, aiming to attract new participants to the options market.
- Product Availability: Initially available through Interactive Brokers Group, these options will soon be offered by other intermediaries, including Charles Schwab, indicating Cboe's proactive response to market demand.
- Historical Context: Cboe first listed binary options in 2008 but withdrew them due to lack of investor interest; this reintroduction reflects the company's adaptation to changing market conditions and renewed confidence.
- Competition and Trends: With the rise of prediction market platforms like Kalshi and Polymarket, Cboe's new product may compete with Nasdaq's binary index options contracts, further driving market innovation.
See More
- Product Innovation: Cboe has launched binary option contracts based on the Mini-S&P 500 Index, marking its first foray into the rapidly growing prediction markets sector, aimed at meeting investor demand for short-term outcome trading.
- Surge in Trading Volume: According to Pew Research Center data, the combined global monthly trading volume on Kalshi and Polymarket skyrocketed from under $5 billion in September last year to approximately $24 billion in April, indicating strong growth potential in prediction markets.
- Platform Access Expansion: Cboe's contracts will initially be available on Interactive Brokers and will gradually roll out to other retail brokerage platforms like Charles Schwab over the coming months, expected to further broaden its market reach.
- Customer Demand Driven: Cboe's head of retail expansion, JJ Kinahan, noted that there is a sustained customer demand for shorter-dated, outcome-based trading, highlighting the company's rapid growth potential in the 0DTE options space.
See More
- New Options Product Launch: Charles Schwab (SCHW) is partnering with Cboe Global Markets (CBOE) to introduce yes-or-no options linked to the S&P 500 index (SP500), expected to launch in the coming months, aiming to attract more investors to the market.
- Innovative Payout Mechanism: The new offerings will feature Cboe's 'plus zone,' allowing traders to receive partial payouts based on how close they are to the target, enhancing trading flexibility and potentially attracting clients with risk management needs.
- Market Competition Analysis: While Schwab's options differ from prediction market futures offered by Kalshi and Polymarket, their binary options operate similarly, providing predetermined cash payouts if clients exceed the index's closing price, thereby strengthening their position in the competitive financial derivatives market.
- Focus on Financial Events: Charles Schwab intends to concentrate on events within the financial sector, having considered contracts linked to other indexes or benchmarks but excluding next year's Super Bowl winners, a strategic choice that will bolster its brand image among professional investors.
See More
- Funding Size: Onco-Innovations intends to issue 6,764,069 units at CAD$0.7392 each, aiming for approximately CAD 5 million in total proceeds to support the ONC010 program and advance its clinical development pathway.
- Subscription Condition: The private placement requires subscriptions for at least 6,764,069 units; if the minimum is not met, all funds will be returned to subscribers in accordance with applicable securities laws, ensuring investor capital protection.
- Warrant Terms: Each unit includes a warrant allowing holders to purchase one share at CAD$0.90 within three years, with an option for the company to accelerate the expiry if the 10-day volume-weighted average price reaches CAD$1.30, enhancing potential returns for investors.
- Use of Proceeds: The net proceeds will be allocated to key stages of the ONC010 program, including manufacturing and preclinical testing, as well as general working capital, demonstrating the company's commitment to ongoing R&D investment and strategic planning.
See More
- Stock Price Decline: CME Group's shares have fallen 19.8% over the past three months, nearing a 52-week low of $244.56, reflecting market concerns over its premium valuation and competitive threats, while investors locked in gains after a strong rally earlier this year.
- Optimistic Earnings Outlook: Based on short-term price targets from 15 analysts, the average target price for CME is $308.80, suggesting a potential upside of 22.3% from the last closing price, indicating market confidence in its future profitability.
- Product Expansion Strategy: CME Group recently launched four new E-mini contracts aimed at broadening its benchmark suite of equity index futures to address growing demand for market risk management tools, further solidifying its position in the equity index ecosystem.
- Strong Capital Returns: As of March 31, 2026, CME Group held $2.6 billion in cash and returned approximately $3.2 billion to shareholders through dividends and share repurchases in Q1 2026, demonstrating its robust financial position and ability to attract income-focused investors.
See More
- Apple Price Increase: Apple plans to raise product prices due to rising memory chip costs, and while its stock has risen 16% over the past three months, it is currently down 7% from earlier this month, which may impact consumer demand and market share.
- Moderna Vaccine Progress: Moderna is making its case for the mRNA flu vaccine before the FDA committee, with shares up 11.6% on Wednesday and nearly 24% over three days, indicating strong market confidence in its product.
- New Highs for Major Banks: Bank of America, Citigroup, Goldman Sachs, JPMorgan, and Morgan Stanley reached new highs on Wednesday, with Bank of America up 9.5% in June, reflecting investor optimism in the financial sector.
- Oil Price Decline: Brent crude oil fell below its 200-day moving average for the first time since February, down over 27% in the past month, which puts pressure on energy stocks and may affect the earnings outlook for related companies.
See More











